Medical University  |  MUSC Hospital  |  Directory
 
Center for Drug and Alcohol Programs

About CDAP


Faculty


Clinical Services


Basic Science Research


Clinical Trials


Research


Recent Publications


Seminars


Highlighted Events


Grand Rounds


Journal Clubs


Training


Job Opportunities


Conferences


Addiction Information

Community Outreach


Podcasts


Videos


Contact Us





CDAP Intranet 



 


  
  

CDAP > Center for Drug and Alcohol Programs Clinical Trials
Center for Drug and Alcohol Programs Clinical Trials

We are currently recruiting participants for the following clinical and non-treatment studies. Each study has age and other requirements and certain clinical exclusions. One advantage of participation is that subjects receive treatment that is free of charge and confidential.  Some studies even provide payment to participants. 

Current Studies
(please select the appropriate heading to learn more about the treatment or non-treatment studies) 
 - Alcohol Treatment Studies
 - Cocaine &Methamphetamine Treatment Studies 
 -
  Non-Treatment Studies

If you are interested in any of these studies, please call the telephone number listed for that study. 

 More information on Clinical Trials at MUSC 

                        ALCOHOL TREATMENT STUDIES                      

Clinical Trial Name: Adolescent Alcohol Treatment
Funding Source: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Principal Investigator: Deborah Deas, MD, MPH
Project Coordinator: Natalie Johnson, MA
Contact Person: Natalie Johnson, MA
Contact Number: 843-876-5070
Study Medications: Naltrexone or Placebo
Therapy: 12 weeks, after twelve week treatment phase, participants will return to the site at 6, 9, and 12 months for follow-up assessments.
                                          Age Requirement: 15-25

Clinical Trial Name: An Exploratory Study of Naltrexone Plus Aripiprazole for Alcohol Dependence
Funding Source: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Principal Investigator: Raymond Anton, MD
Project Coordinator: Pat Latham, RN, PhD, CS or Alicia Baros, PhD
Contact Person: Pat Latham, RN, PhD, CS or Alicia Baros, PhD
Contact Number: 843-792-2727 or 843-792-1230 or 843-792-0073
Study Medications: Naltrexone/Placebo, Naltrexone/Aripiprazole, or Placebo/Placebo
Therapy: Individual Medical Management Sessions over 16 weeks
Age Requirement: 18-70

Clinical Trial Name: A Phase 2 Study of LY2196044 Compared with Placebo   
 
in the Treatment of Alcohol Dependence
  Funding Source: Eli Lilly and Company
  Principal Investigator: Raymond Anton, MD
  Project Coordinator: Pat Latham, RN, PhD, CS or Alicia Baros, PhD
  Contact Person: Pat Latham, RN, PhD, CS or Alicia Baros, PhD
  Contact Number: 843-792-2727 or 843-792-1230 or 843-792-0073
  Study Medications: LY2196044/Placebo
  Therapy: Individual Medical Management Sessions over 16 weeks
  Age Requirement: 21-65

  Clinical Trial Name: Genetic and brain mechanisms of naltrexone’s treatment 
  efficacy for alcoholism
  Funding Source: NIAAA
  Principal Investigator: Raymond Anton, MD
  Project Coordinator: Konstantin E. Voronin, MD, Ph.D
  Contact Person: Konstantin E. Voronin, MD, Ph.D
  Contact Number: 843-792-2727
  Study Medications: Naltrexone/Placebo
  Therapy: Individual Medical Management Sessions over 16 weeks
  Age Requirement: 18-70

  Clinical Trial Name: A Phase II Multicenter, Randomized, Double-Blind, Two-
  Stage Clinical Trial to Evaluate the Efficacy and
 
Safety of MK-0594 in Patients with Alcohol Dependence.
  Funding Source: Merck & Co., Inc
  Principal Investigator: Raymond Anton, MD
  Project Coordinator: Konstantin E. Voronin, MD, Ph.D
  Contact Person: Konstantin E. Voronin, MD, Ph.D
  Contact Number: 843-792-2727
  Study Medications: MK-0594/Placebo
  Therapy: Individual Medical Management Sessions over 12 weeks
  Age Requirement: at least 21 years old

     COCAINE & METHAMPHETAMINE TREATMENT STUDIES     

Clinical Trial Name: Modafinil and CBT for Cocaine Addiction
Funding Source: National Institute on Drug Abuse (NIDA)
Principal Investigator: Robert Malcolm, MD
Research Assistant: Kelley Barnes, BA
Contact Person: Melissa Corley, MA
Contact Number: 843-792-2727
Study Medications: Modafinil or Placebo
Therapy: 8 weekly sessions of Cognitive Behavioral Therapy (CBT)
Frequency of visits: Tri-weekly visits, 1-2 week screening period, 8 week treatment period and 2
                                         
follow-up visits.
                                        
  Age Requirement: 18-65

 Clinical Trial Name: A Controlled Trial of N-Acetylcysteine for the Treatment of
 Cocaine Dependence
 Funding Source: National Institute on Drug Abuse (NIDA)
 Principal Investigator: Robert Malcolm, MD
 Project Coordinator: Kristi Huebner, MPH
 Contact Person: Melissa Corley, MA
 Contact Number: 843-792-2727
 Study Medications: N-Acetylcysteine or Placebo
 Therapy: Cognitive Behavioral Therapy (CBT)
 Frequency of visits: Tri-weekly visits
 Age Requirement: 18-65  

NON-TREATMENT STUDIES


CDAP also recruits participants for non-treatment laboratory studies. These studies help us learn about basic biological, genetic or behavioral aspects of alcohol use and abuse. Many of these studies provide payment to participants.

Study Name: Clinical Circuitry Underlying Methamphetamine Cue Craving and Cue Extinction
Funding Source: National Institute on Drug Abuse (NIDA)
Principal Investigator: Robert Malcolm, MD
Project Coordinator: Kristi Huebner, MPH
Contact Person: Melissa Corley, MA
Contact Number: 843-792-2727
Study Medications: None
Therapy: None
Age Requirement: 18-65

Study Name: Effects on Medication Treatment on Cue-Induced Brain Activation in Alcoholics
Funding Source: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Principal Investigator: Hugh Myrick, MD
Project Coordinator: Scott Henderson, BA
Contact Person: Scott Henderson, BA
Contact Number: 843-792-5560
Study Medications: Aripiprazole/Chantix/Placebo
                                         Therapy: None
                                         Age Requirement: 21-65

Study Name: Evaluating the Genetic Variability of Naltrexone Response
Funding Source: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Principal Investigator: Raymond Anton, MD
Project Coordinators: Konstantin Voronin, MD, PhD or Abraham Tiffany, BS
Contact Person: Abraham Tiffany, BS
Contact Number: 843-792-9955
Study Medications: Naltrexone/Placebo
Therapy: None
Age Requirement: 21-65



Study Name: Personality and Alcohol Preference
Funding Source: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Principal Investigator: Suzanne Thomas, PhD
Research Assistant: Kathryn Morrow, BS
Contact Person: Kathryn Morrow, BS
Contact Number: 843-792-5811
Study Medications: None
                                         Therapy: None
                                         Age Requirement: 21-65

 Study Name: Personality and Alcohol Discrimination
 Funding Source: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
 Principal Investigator: Suzanne Thomas, PhD
 Research Assistant: Kathryn Morrow, BS
 Contact Person: Kathryn Morrow, BS
 Contact Number: 843-792-4406
 Study Medications: None
 Therapy: None
 Age Requirement: 21-40


You can make a difference - donate to CDAP. For easy online giving, please click here and choose "Center for Drug and Alcohol Programs" in the designation drop down box.


  

Helpful Links